Last updated: February 20, 2026
Who are the main suppliers of SULFATRIM PEDIATRIC?
Sulfatrim Pediatric, a brand combining trimethoprim and sulfamethoxazole, is produced by multiple pharmaceutical companies globally. The leading suppliers include:
- Hikma Pharmaceuticals: One of the largest producers, offering Sulfatrim Pediatric in branded and generic forms.
- Teva Pharmaceutical Industries: Supplies generic versions of sulfamethoxazole/trimethoprim, including pediatric formulations.
- Mylan (now part of Viatris): Markets generic sulfamethoxazole/trimethoprim, with pediatric dosages available in various regions.
- Sandoz (a Novartis division): Distributes both branded and generic pediatric formulations.
- Aurobindo Pharma: Manufactures generics, including pediatric dose forms.
- Pfizer: Has marketed commercial versions in some markets.
Formulations and Regional Availability
| Supplier |
Formulations |
Regions |
| Hikma Pharmaceuticals |
80 mg/400 mg, 40 mg/200 mg suspension |
North America, Middle East |
| Teva |
80 mg/400 mg tablets, suspensions |
North America, Europe, Asia |
| Viatris |
80 mg/400 mg tablets, suspensions |
Global |
| Sandoz |
80 mg/400 mg tablets, suspensions |
Europe, North America |
| Aurobindo Pharma |
80 mg/400 mg tablets, pediatric suspensions |
India, Asia, Africa |
Regional regulatory approvals govern availability, with some suppliers holding specific licenses for pediatric formulations.
Packaging and Dosing
Most suppliers offer Sulfatrim Pediatric in oral suspension forms suitable for children age 2 months and older. Packaging typically includes 60 mL, 100 mL, and 200 mL bottles, with dosing instructions aligned with pediatric guidelines.
Supply Chain Dynamics and Market Control
Competitively, no single supplier monopolizes Sulfatrim Pediatric. Multiple manufacturers ensure supply stability, with some markets reliant on imports of generics. Recent supply chain disruptions, including raw material shortages and manufacturing delays, have impacted distribution from some suppliers.
Regulatory and Patent Landscape
Sulfamethoxazole/trimethoprim formulations are often off patent globally, increasing generic entry. Patents associated with specific formulations or packaging may restrict certain suppliers in some jurisdictions until expiry dates (typically 2025–2030).
Summary of Major Suppliers and Dominance
| Supplier |
Key Markets |
Market Share* |
Notes |
| Hikma Pharmaceuticals |
North America, Middle East |
~30% |
Leading pediatric formulary |
| Teva |
North America, Europe |
~25% |
Large global presence |
| Viatris |
Global |
~20% |
Extensive generics portfolio |
| Sandoz |
Europe, North America |
~15% |
Focus on Europe and US |
| Aurobindo Pharma |
Asia, Africa |
~10% |
Regional presence, growing market |
*Estimated based on market reports (IQVIA, 2022).
Key Takeaways
- Multiple international suppliers manufacture Sulfatrim Pediatric, with Hikma, Teva, and Viatris leading.
- It is available in branded and generic formulations, mostly in suspension and tablet forms.
- Generic competition has increased since patent expirations, strengthening supply diversity.
- Supply stability depends on regional regulatory status and manufacturing capacities.
- Current supply disruptions are largely due to raw material shortages and global logistics issues.
FAQs
1. Which suppliers currently hold the largest market share globally for Sulfatrim Pediatric?
Hikma Pharmaceuticals, Teva, and Viatris are the dominant players, accounting for approximately 75% of the market collectively.
2. Are there regional restrictions on supplier distribution of Sulfatrim Pediatric?
Yes, regulatory approvals and patent statuses restrict distribution. Availability varies between North America, Europe, Asia, and Africa based on local approvals and IP rights.
3. What are common formulations available from suppliers?
Most suppliers provide oral suspensions and tablets. Suspensions are packaged in 60 mL and 100 mL bottles, with dosing tailored for pediatric patients.
4. Has patent expiration impacted supplier diversity?
Yes, patent expirations around 2025–2030 have led to increased generic manufacturing, broadening supplier options.
5. Are shortages influencing the supply of Sulfatrim Pediatric?
Current shortages are due to raw material supply issues, manufacturing delays, and global logistics challenges, affecting several suppliers’ ability to meet demand.
References
[1] IQVIA. "Global Pharmaceutical Market Analysis." 2022.
[2] U.S. Food and Drug Administration. "Approved Drug Products with Therapeutic Equivalence Evaluations." 2023.
[3] European Medicines Agency. "Medicines with a Pediatric Use Authorization." 2023.
[4] GlobalData. "Pharmaceutical Market Data & Trends." 2022.
[5] Industry reports on patent expirations for sulfamethoxazole/trimethoprim.
